AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC.
Antisense oligonucleotides (ASOs) that promote IL7R exon 6 inclusion to reduce pathogenic sIL7R levels in multiple sclerosis
- Sector
- Biotech
- Headquarters
- HOUSTON, TX
- Founded
- 2020
- Latest Form D
- $2.2M, Nov 2024
- Total capital
- $4.9M
- Federal grants
- $2.7M
- 7 awards · 2019–2023
- Rank in peer group#379 of 514
- Private capital raised
- $2.2M
- 1 Form D · last Nov 2024
- 23 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$2.2M
- Federal grantHealth and Human S · Phase II · Development of a novel accurate therapy for multiple sclerosis$404K
- Federal grantHealth and Human S · Phase II · Development of a novel accurate therapy for multiple sclerosis$1M
- Federal grantHealth and Human S · Phase I · Strategy for specific delivery of antisense oligonucleotides to T cells$307K
- Federal grantHealth and Human S · Phase I · Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy$325K
- Federal grantHealth and Human S · Phase I · Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells$284K
- Federal grantHealth and Human S · Phase I · Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cells$170K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Development of a novel accurate therapy for Multiple Sclerosis$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
70months
from AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC.’s first federal award to its first private round.
- First federal award · Jan 2019
- Health and Human S · $225K
- First Form D · Nov 2024
- $2.2M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Gaddiel Galarza-MunozResearcherExecutive OfficerLinked by $2.7M in grants as PI
- Brock ReeveDirectorNamed in SEC Form D filings
- Eugene WilliamsExecutive Officer, DirectorNamed in SEC Form D filings
- Jimmy LuDirectorNamed in SEC Form D filings
- Mariano Garcia-BlancoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingAnti-soluble INTERLEUKIN-7 Receptor Antibody Therapy To Treat Autoimmune DiseasesUSPTOApplication 19295663
- PendingAnti-soluble INTERLEUKIN-7 Receptor Antibody Therapy To Treat Autoimmune DiseasesUSPTOApplication 18856623
Related companies, and why
- AJK BIOPHARMACEUTICAL LLCSimilar federal contract value in Biotech · null in contracts
- GALIBRA NEUROSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Arena PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- NOUS BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
- GENTIBIO, INC.Similar federal contract value in Biotech · null in contracts
- Phenzyme, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .